Clinical Trial Update: Efficiency and Safety of Paxlovid for COVID-19 Patients With Severe Chronic Kidney Disease [Phase 4]

View source ↗

Summary

A Phase 4 trial updating on the efficiency and safety of Paxlovid in COVID-19 patients with severe chronic kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• PAXLOVID (Nirmatrelvir and ritonavir)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: COVID-19, Renal Insufficiency, Chronic | Phase 4 | Status: UNKNOWN